Fibrocell Science Announces Proposed Public Offering of Common Stock

  Fibrocell Science Announces Proposed Public Offering of Common Stock

Business Wire

EXTON, Pa. -- September 25, 2013

Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company
focused on the development of innovative products for aesthetic, medical and
scientific applications, today announced its intention to offer and sell,
shares of its common stock in an underwritten public offering pursuant to its
existing shelf registration statement. The company also intends to grant to
the underwriters a 30-day option to purchase up to an additional 15% of the
shares of common stock sold in the public offering to cover over-allotments,
if any. The company intends to use the net proceeds from the offering to fund
Phase III clinical trials for additional azficel-T indications, to progress
its collaboration programs with Intrexon Corporation and for working capital
and general corporate and administrative expenses.

Barclays is acting as sole book running manager and representative of the
underwriters for the offering. Wedbush PacGrow Life Sciences and Griffin
Securities are acting as co-managers for the offering.

The securities described above are being offered by Fibrocell Science pursuant
to a registration statement previously filed and declaredeffective by the
Securities and Exchange Commission. This press release does not constitute an
offer to sell or a solicitation of an offer to buy the securities in this
offering. The offering may be made only by means of a prospectus, copies of
which may be obtained, when available, from Barclays Capital Inc. by calling
1-888-603-5847, or by mail at Barclays Capital Inc. c/o Broadridge
FinancialSolutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by e-mail
at Barclaysprospectus@broadridge.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
focused on the development of innovative products for aesthetic, medical and
scientific applications. Fibrocell Science is committed to advancing the
scientific, medical and commercial potential of autologous skin and tissue, as
well as its innovative cellular processing technology and manufacturing
excellence. For additional information, please visitwww.fibrocellscience.com.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking
statements.Forward-looking statements include, without limitation, the
company’s ability to complete the proposed public offering of its common stock
described above. These forward-looking statements are based upon our current
expectations and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business.Although management believes that the plans and objectives reflected
in or suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. Accordingly, investors should
not place any reliance on forward-looking statements as a prediction of actual
results.

Contact:

Fibrocell Science, Inc.
Gregory Weaver, +1-484-713-6000
Chief Financial Officer
gweaver@fibrocellscience.com
 
Press spacebar to pause and continue. Press esc to stop.